肾移植受者单抗原磁珠法检测人类白细胞抗原DP抗体

目的 采用单抗原磁珠法检测肾移植患者的人类白细胞抗原DP(HLA-DP)抗体,并探讨HLA-DP抗体与移植肾功能的关系。方法 采用流式细胞学单抗原磁珠法检测了323例患者的血清,这些患者来自4个不同的中心,并分为有功能组和排斥组。应用c2检验比较两组抗体例数的差异。结果 在138例有功能组的肾移植患者血清中有5.1﹪检测到HLA-DP抗体,而排斥组的185例患者血清中有19.5﹪检测到HLA-DP抗体(c2=14.176,P=0.000)。在有功能组和排斥组中分别有42.9﹪和63.9﹪的HLA-DP抗体阳性患者同时有DR/DQ抗体。在没有HLA-I类及DR/DQ抗体的患者中,在排斥组中有14.3﹪的患者可检测出HLA-DP抗体,而有功能组中只有3.5﹪有HLA-DP抗体(c2=7.165,P=0.007)。在排斥组中,DP0301的检出频率最高。结论 相对于有功能组来说,HLA-DP?抗体在排斥组中有更高的检出率。特别是对于再次移植的患者来说,应该作HLA-DP的组织配型以避免HLA-DP等位基因引起的致敏。     

组织相容性Ⅰ类相关链A位点基因多态性在预判肾移植物排斥中的意义

目的 研究组织相容性Ⅰ类相关链A位点(MICA)基因多态性和抗MICA特异性抗体在肾移植排斥反应发生中的意义.方法 采用免疫磁珠液相芯片技术对40例肾移植患者在移植术前和移植术后1个月、3个月、6个月、1年和2年动态检测抗MICA抗体的特异性和阳性分值的变化,同时采用SSOP方法分析16对肾移植供受者的MICA基因分型...     

LIVIN和HLA-I类分子在肾透明细胞癌中的表达及其临床意义

目的:探讨凋亡抑制蛋白Livin与人类白细胞抗原(HLA)I类分子在人类肾脏透明细胞癌(clear cell renal cell carcinoma,ccRCC)中的表达及其临床意义。方法:选择哈尔滨医科大学附属第一医院2007年12月至2011年12月收治的拟行肾癌根治术的患者80例,应用免疫组织化学方法检测80例ccRCC组织与10例癌旁正常肾组织中Livin及HLA-I类分子的表达,并分析其与患者临床病理特征之间的关系。结果:10例癌旁正常肾组织中均未见Livin的阳性表达,而HLA-I类分子的阳性表达率为100%。ccRCC组织中,Livin的阳性表达率及HLA I类分子表达下调百分率分别为41(51.25%)例和48(60.00%)例,Livin的阳性表达率与正常组相比差异有统计学差异(P0.05)。ccRCC组织中Livin的阳性表达率与淋巴结转移、组织分化程度显著相关(P0.05),而HLA I类分子的表达下调百分率与患者的性别、年龄、肿瘤分级、淋巴结转移及分期均无相关性(P0.05)。ccRCC组织中Livin的表达与HLA I类分子的表达亦无显著相关性(P0.05)。结论:Livin、HLA I类分子表达异常参与了ccRCC的发生、发展过程,Livin可能成为ccRCC的一个重要预后指标和治疗靶点。     

肾移植受者生活质量和健康素养现状调查及影响因素分析

目的:调查肾移植受者生活质量(QOL)、健康素养(HL)现状,并分析其QOL、HL的影响因素。方法:选择我院2015年1月～2016年1月收治的369例肾移植受者为研究对象,采用自制问卷结合病历信息的方式收集入选患者的临床资料,分别采用健康状况调查简表(SF-36)、中文版成人快速健康素养评估量表(REALAM-T)对肾移植受者的QOL、HL的现状进行调查,并分析肾移植受者QOL、HL的影响因素。结果:369例肾移植受者QOL评分为(561.08±54.95)分,HL评分为(62.75±5.26)分,其中288例(78.05%)患者处于HL充足水平,56例(15.18%)患者处于HL临界水平,25例(6.78%)患者处于HL缺乏水平。单因素分析结果显示,不同婚姻状况、家庭人均月收入、文化程度、费用支付方式、移植肾来源、移植术后时间的肾移植受者QOL评分比较差异有统计学意义(P0.05);不同家庭人均月收入、文化程度、费用支付方式、移植肾来源、移植术后时间的肾移植受者HL评分比较差异有统计学意义(P0.05)。多元线性回归分析显示,家庭人均月收入、费用支付方式、移植肾来源、移植术后时间是肾移植受者QOL的影响因素(P0.05),文化程度、移植肾来源、移植术后时间是肾移植受者HL的影响因素(P0.05)。结论:肾移植受者QOL较差,HL整体不高,家庭人均月收入、费用支付方式、移植肾来源、移植术后时间是肾移植受者QOL的影响因素,文化程度、移植肾来源、移植术后时间是肾移植受者HL的影响因素,临床应根据以上因素采取针对性的措施,以提高肾移植受者的QOL和HL。     

抗RA33 抗体与幼年特发性关节炎的诊断意义

目的:通过检测幼年特发性关节炎(JIA)患者血清中的抗RA33抗体,了解抗RA33抗体与幼年特发性关节炎的临床诊断价值。方法:采用酶联免疫固相分析检测81例JIA患儿(女19名,男62名,平均年龄8.6岁,平均病程1.4年)血清中抗RA33抗体、RF,同时以55例儿童系统性红斑狼疮(SLE)等其他关节性疾病或病毒感染患者和49例健康儿童作为对照组。阴阳性结果判断均采用试剂盒推荐的临界值。结果:81例JIA患儿中抗RA33抗体阳性率为11.11%(9/81),RF阳性率为12.35%(10/81),特异性均为91.35%;JIA组与正常对照组抗RA33抗体阳性率比较有统计学意义(P<0.05),与其他关节性疾病对照组比较差异无显著性(P>0.05)。JIA组中抗RA33抗体的检出与RF无相关性(P>0.05);在JIA各亚型中抗RA33抗体主要存在于全身型和多关节型,各占33.3%和25.0%,RF则只出现于多关节型,占62.5%。两者比较有显著性差异(P<0.05)。81例JIA患儿中共有18例关节出现影像学改变,其中4例抗RA33抗体阳性(22.2%),与未发生影像学改变的JIA患儿比较无显著性差异(P>0.05)。结论:抗RA33抗体尚不能作为JIA早期诊断的新的可靠性指标,抗RA33抗体主要见于全身型和多关节型,对JIA的分型有指导意义。     

超微血流成像术用于肾移植患者术后评估的临床价值分析

目的:探讨超微血流成像术用于肾移植患者术后评估的临床价值。方法:选取我院2019年2月-2019年8月收治的60例肾移植患者的临床资料,根据术后恢复情况分为A、B、C三组,A组(27例,术后肾功能恢复良好)、B组(20例,术后发生过敏肾功能异常病变但治疗后肾功恢复正常)、C组(13例,术后血肌酐水平持续增高肾功能异常者),三组均采用超微血管流成像术检测血管指数,比较不同组患者的血管指数并分析其与血肌酐水平的关系。结果:三组患者的肾移植长径、前后径、左右径、皮质厚度、叶间动脉阻力指数比较无显著差异(P0.05)。C组患者的肾皮质血管指数(23.34±6.03%)明显低于A组(33.23±3.45%)、B组(31.23±4.23%)(P0.05)。肾功能异常患者肾皮质的血管指数较低,且随着血肌酐水平的升高而下降,两者呈显著负相关(r=-0.23,P0.05)。结论:超声微血流成像术用于肾移植患者术后评估可较好地反映肾皮质血供及术后肾功能的变化。     

抗t-PA抗体水平和血栓的相关性研究

目的:研究自身免疫性疾病病人抗t-PA抗体水平和病人血栓形成之间的关系。方法:用酶联免疫吸附法(ELISA)检测原发性抗磷脂综合症和红斑狼疮患者(32例狼疮样抗凝物阳性,32例狼疮样抗凝物阴性)与40例健康对照的IgG类抗t-pA抗体的水平,用Pearson Chi-Square test的方法分析了病人体内IgG类抗t-PA抗体水平和血栓之间的相关性。结果:本试验研究的病人群体中IgG类抗t-PA抗体阳性的有13(20.3%)个,并且我们的研究表明IgG类抗t-PA抗体阳性和血栓病史显著相关(P=0.04)。结论:原发性抗磷脂综合症和红斑狼疮病人群体中有较高的IgG类抗t-PA抗体水平,它们可能和病人体内血栓的发生有关。     

不规则抗体筛查对临床安全输血的意义

目的:不规则抗体是血浆中除了抗A、抗B以外的其他血型抗体,会引起血型鉴定困难、疑难配血、溶血性输血反应及新生儿溶血症。本文探讨不规则抗体在住院患者中的发生情况,为需要输血的患者选择匹配的血液供应,确保临床输血安全、合理、有效。方法:利用Ⅰ~Ⅲ类谱细胞用微柱凝胶抗人球蛋白检测卡对住院患者血标本进行不规则抗体筛查,再对阳性标本利用Ⅰ~Ⅻ类谱细胞进行特异性鉴定。结果:13889例受检血标本中,检出不规则抗体25例,阳性率为0.18%。检出的不规则抗体涉及Rh、MNSs、Lewis、Kidd四个血型系统,所占比例分别为80%、8%、8%、4%。且不规则抗体在女性患者中的检出率高于男性患者。结论:输血前对患者进行不规则抗体筛查及特异性鉴定,可有效减少和避免溶血性输血反应的发生,对于安全输血是十分必要的。     

慢性移植肾病中高内皮微静脉新生与树突状细胞的关系

目的探讨慢性移植肾病肾组织内树突状细胞(dendritic cell,DC)与高内皮微静脉(high endothelial venlues,HEVs)新生的相关性。方法收集20例经病理确诊为慢性移植肾病并行移植肾切除的肾组织标本,免疫组织化学检测HEVs及DC、CD5~+/CD19~+B淋巴细胞等各自标志物的免疫反应性;根据PAS、HE染色,用肾移植Banff1997标准进行病理评分。统计分析3类细胞和各病理变化指标在HEVs(+)组和HEVs(-)组间的差异。结果 20例样本中有3例呈HEVs标志物MECA-79免疫反应阳性,即HEVs(+),占15%;17例MECA-79免疫反应阴性,即HEVs(-),占85%。HEVs(+)组CD5+B淋巴细胞、CD19~+B淋巴细胞数量比HEVs(-)组相应阳性细胞多,但差异无显著性;标志物CD208阳性的DC数在HEVs(+)组较HEVs(-)组明显增多。移植肾Banff 1997病理评分显示,HEVs(+)组所有病变指标评分虽均高于HEVs(-)组,但亦无统计学意义。结论慢性移植肾病肾组织存在HEVs的新生,可能参与肾脏炎症微环境的形成;DC可能与HEVs的生成有关。     

肾移植急性排异冲击治疗合并低血钾1例抢救的护理体会

肾移植急性排异是移植肾功能发生常,患者的肾功能指标突然升高,出现尿量减少,水肿等症状,目前多采用冲击治疗。2005年3月10日我科收治一例移植肾排异的患者,入院后采用冲击治疗,出现严重的低血钾症状,并成功获得抢救。现将该病例救治的护理体会总结如下:临床资料患者男性,33岁,体重136kg。于2000年行肾移植手术至今,20日前患者无明显诱因出现恶心,厌食,伴血压升高150/100mmhg,近1周出现低热,体温在37.5℃左右,移植肾区不适,尿量明显减少,每日在700ml以下,肾功能检查cr3.0mg/dl,诊断:肾移植急性排异,于2005年3月10日入院。应用甲强龙500mg连…     

Prognostic markers for survival in patients with metastatic renal cell carcinoma treated with interleukin-2

 Interleukin-2 (IL-2)-based immunotherapy can induce antitumor responses in about 25% of patients with metastatic renal cell carcinoma (RCC). The limited effect and the severe side-effects of IL-2 have led us to perform a prognostic factor analysis. Twenty-four patients with metastatic RCC were treated with IL-2. Flow cytometry and immunohistology were used to determine DNA ploidy, HLA-II expression on tumor cells, and the presence of macrophages in the primary tumor. These variables were examined in relation to survival. The 4-year overall survival rate was 38%. Forty-six percent of the primary tumors were aneuploid. All tumors, except one, showed HLA-II expression and macrophage presence. A statistically significant correlation (r = 0.66, P = 0.002) was found between HLA-II expression and macrophage presence. Patients with high HLA-II expression had a lower 4-year survival (22% compared to 50%), as had patients with high macrophage presence (20% compared to 42%). Of note, patients characterized by both high HLA-II and high macrophage expression had the worst survival (13% compared to 50%). We concluded that DNA ploidy was not predictive for survival, whereas HLA-II expression and macrophage presence may represent valuable prognostic factors related to survival. The present data suggest that more of the patients with no or moderate HLA-II expression and/or no or moderate macrophage presence in the primary tumor could survive with persistance of their malignant disease after having received IL-2 immunotherapy, as compared to patients with both high HLA-II and high macrophage expression. Received: 2 April 1996 / Accepted: 15 October 1996     

Gene Classification Using Codon Usage and Support Vector Machines

Abstract-- A novel approach for gene classification, which adopts codon usage bias as input feature vector for classification by support vector machines (SVM) is proposed. The DNA sequence is first converted to a 59-dimensional feature vector where each element corresponds to the relative synonymous usage frequency of a codon. As the input to the classifier is independent of sequence length and variance, our approach is useful when the sequences to be classified are of different lengths, a condition that homology-based methods tend to fail. The method is demonstrated by using 1,841 Human Leukocyte Antigen (HLA) sequences which are classified into two major classes: HLA-I and HLA-II; each major class is further subdivided into sub-groups of HLA-I and HLA-II molecules. Using codon usage frequencies, binary SVM achieved accuracy rate of 99.3% for HLA major class classification and multi-class SVM achieved accuracy rates of 99.73% and 98.38% for sub-class classification of HLA-I and HLA-II molecules, respectively. The results show that gene classification based on codon usage bias is consistent with the molecular structures and biological functions of HLA molecules.     

Therapeutic efficacy of anti‐MMP9 antibody in combination with nab‐paclitaxel‐based chemotherapy in pre‐clinical models of pancreatic cancer

Matrix metalloproteinase 9 (MMP9) is involved in the proteolysis of extracellular proteins and plays a critical role in pancreatic ductal adenocarcinoma (PDAC) progression, invasion and metastasis. The therapeutic potential of an anti‐MMP9 antibody (αMMP9) was evaluated in combination with nab‐paclitaxel (NPT)‐based standard cytotoxic therapy in pre‐clinical models of PDAC. Tumour progression and survival studies were performed in NOD/SCID mice. The mechanistic evaluation involved RNA‐Seq, Luminex, IHC and Immunoblot analyses of tumour samples. Median animal survival compared to controls was significantly increased after 2‐week therapy with NPT (59%), Gem (29%) and NPT+Gem (76%). Addition of αMMP9 antibody exhibited further extension in survival: NPT+αMMP9 (76%), Gem+αMMP9 (47%) and NPT+Gem+αMMP9 (94%). Six‐week maintenance therapy revealed that median animal survival was significantly increased after NPT+Gem (186%) and further improved by the addition of αMMP9 antibody (218%). Qualitative assessment of mice exhibited that αMMP9 therapy led to a reduction in jaundice, bloody ascites and metastatic burden. Anti‐MMP9 antibody increased the levels of tumour‐associated IL‐28 (1.5‐fold) and decreased stromal markers (collagen I, αSMA) and the EMT marker vimentin. Subcutaneous tumours revealed low but detectable levels of MMP9 in all therapy groups but no difference in MMP9 expression. Anti‐MMP9 antibody monotherapy resulted in more gene expression changes in the mouse stroma compared to the human tumour compartment. These findings suggest that anti‐MMP9 antibody can exert specific stroma‐directed effects that could be exploited in combination with currently used cytotoxics to improve clinical PDAC therapy.     

Outcome of renal replacement treatment in patients with diabetes mellitus.

OBJECTIVE--To compare the outcome of renal replacement treatment in patients with diabetes mellitus and in non-diabetic patients with end stage renal failure. DESIGN--Retrospective comparison of cases and matched controls. SETTING--Renal unit, Western Infirmary, Glasgow, providing both dialysis and renal transplantation. PATIENTS--82 Diabetic patients starting renal replacement treatment between 1979 and 1988, compared with 82 matched non-diabetic controls with renal failure and 39 different matched controls undergoing renal transplantation. MAIN OUTCOME MEASURES--Patient characteristics, history of smoking, prevalence of left ventricular hypertrophy and myocardial ischaemia at start of renal replacement treatment; survival of patients with renal replacement treatment and of patients and allografts with renal transplantation. RESULTS--The overall survival of the diabetic patients during the treatment was 83%, 59%, and 50% at one, three, and five years. Survival was significantly poorer in the diabetic patients than the controls (p less than 0.001). Particularly adverse features for outcome at the start of treatment were increasing age (p less than 0.01) and current cigarette smoking (relative risk (95% confidence interval) 2.28 (0.93 to 4.84), p less than 0.05). Deaths were mainly from cardiac and vascular causes. The incidence of peritonitis in patients on continuous ambulatory peritoneal dialysis was the same in diabetic patients and controls (49% in each group remained free of peritonitis after one year), and the survival of renal allografts was not significantly worse in diabetic patients (p less than 0.5). CONCLUSIONS--Renal replacement treatment may give good results in diabetic patients, although the outlook remains less favourable than for non-diabetic patients because of coexistent, progressive vascular disease, which is more severe in older patients.     

Free androgen index is superior to total testosterone for short-term assessment of the gonadal axis after renal transplantation

OBJECTIVE: Recent studies have assessed gonadal function in association with different immunosuppressive drugs in transplanted patients mainly relying on the measurement of total testosterone. It is the aim of this study to assess the short-term changes of the hypothalamic-pituitary-gonadal axis following renal transplantation using the free androgen index (FAI). PATIENTS AND METHODS: The sequential changes in total testosterone, sex hormone-binding globulin (SHBG), gonadotropin and prolactin concentrations were measured in 22 male patients before and after 1-3 days, and 1, 2 and 3 weeks following renal transplantation. RESULTS: Total testosterone and SHBG concentrations dropped significantly after transplantation (total testosterone: baseline: 15.2 +/- 1.6 nmol/l vs. 1 week: 7.9 +/- 0.8 nmol/l vs. 2 weeks: 9.8 +/- 0.9 nmol/l, SHBG: baseline: 29.9 +/- 3.2 nmol/l vs. 1 week: 19.9 +/- 2.1 nmol/l, 2 weeks: 18.9 +/- 2.4 nmol/l, p < 0.01). FAI decreased significantly after day 1-3 returning to values near baseline thereafter (baseline: 60 +/- 9% vs. day 1-3: 38 +/- 6%, 2 weeks: 61 +/- 7%; p < 0.01). There was a significant positive correlation between FAI and renal function. CONCLUSION: Measurement of the free androgen index is superior to total testosterone for assessment of the pituitary-gonadal axis in the first weeks after renal transplantation.     

Organ transplantation in Bulgaria

The transplantation program in Bulgaria started in 1968 with renal transplantations to a child and adult woman. In 1986 the first heart transplantation was performed. To date a total of 10 heart transplants have been performed, including one combined heart/lung. A liver transplantation program was launched in 2005 with a total number of 16 transplantations—7 from living donors and 9 from deceased donors. The highest transplantation activity is registered in the field of renal transplantation. During the period 1980–2006, 462 Bulgarian recipients of kidney were transplanted in Bulgaria. The ratio between transplantations from deceased and living related donors is approximately 1:0.9. Annual transplantation activity varies among the years from 1 to 12 renal transplantations p.m.p./per year. The 1- (80.7% vs. 63.1%), 5- (57.86% vs. 39.0%) and 10-year (42.65% vs. 23.62%) graft survival rates are higher for recipients of living donor kidneys compared to those of deceased donor. In 1983 a National kidney waiting list was established. Currently the number of the registered patients eligible for renal transplantation is 885. The proportion of sensitized patients in the waiting list is 20.45% and 4.34% of them are hyperimmunized. Recently HLAMatchmaker program has been implemented not only for sensitized patients but also for those with rare alleles and haplotypes. Post-transplant immunological monitoring showed a strong association between alloantibody presence and delayed graft function (Chi-square = 10.73, P < 0.001), acute rejection (Chi-square = 14.504, P < 0.001), chronic rejection (Chi-square = 12.84, P < 0.001) and graft loss (Chi-square = 20.283, P < 0.001). Based on the experience in our transplant center a strategy for improvement of long-term renal graft survival was developed and implemented.     

Presentation,management, complications,and outcome of acute renal failure in childhood: five years' experience.

During 1971-5, 72 episodes of acute renal failure were treated in 70 children aged up to 16 years. The commonest causes were renal hypoperfusion (31 cases), haemolytic-uraemic syndrome (12), glomerulonephritis (9), septicaemia (5), and congenital abnormalities (6). Though referral from other hospitals was generally prompt, 10 out of 51 patients had been observed for up to seven days before transfer. Dailysis was used in 44 cases, the most common complications of which were peritonitis in those treated with peritoneal dialysis and acute changes in fluid balance in those treated with haemodialysis. Altogether 37 patients fully recovered, 10 were discharged with chronically impaired renal function, 17 died, and six entered the dialysis and transplantation programme. The mortality fell from 33% in 1972 to 20% in later years, which was due solely to maintenance dialysis being available. Though all patients with irrevocable kidney failure who were suitable entered the dialysis and transplantation programme, with current financial restrictions we doubt whether we shall be able to find places for all such patients in the future.     

Outcomes of Renal Transplantation in HIV-1 Associated Nephropathy

Introduction

Several studies have demonstrated that renal transplantation in HIV positive patients is both safe and effective. However, none of these studies have specifically examined outcomes in patients with HIV-associated nephropathy (HIVAN).

Methods

Medical records of all HIV-infected patients who underwent kidney transplantation at Johns Hopkins Hospital between September 2006 and January 2014 were reviewed. Data was collected to examine baseline characteristics and outcomes of transplant recipients with HIVAN defined pathologically as collapsing focal segmental glomerulosclerosis (FSGS) with tubulo-interstitial disease.

Results and Discussion

During the study period, a total of 16 patients with HIV infection underwent renal transplantation. Of those, 11 patients were identified to have biopsy-proven HIVAN as the primary cause of their end stage renal disease (ESRD) and were included in this study. They were predominantly African American males with a mean age of 47.6 years. Seven (64%) patients developed delayed graft function (DGF), and 6 (54%) patients required post-operative dialysis within one week of transplant. Graft survival rates at 1 and 3 years were 100% and 81%, respectively. Acute rejection rates at 1 and 3 years were 18% and 27%, respectively. During a mean follow up of 3.4 years, one patient died.

Conclusions

Acute rejection rates in HIVAN patients in this study are higher than reported in the general ESRD population, which is similar to findings from prior studies of patients with HIV infection and ESRD of various causes. The high rejection rates appear to have no impact on short or intermediate term graft survival.     

O‐8FALSE NEGATIVE BRONCHIAL CYTOLOGY

Introduction: BK virus nephropathy is an emerging cause of renal transplant failure accounting for allograft loss in 45–50% of recipients between 2–60 months post‐transplantation. The Renal Transplant Unit in Royal Free Hospital has devised a local surveillance programme for screening renal transplant patients at weekly intervals by urinary cytology (UC) and electron microscopy (EM), and confirmation of positive results by plasma PCR and allograft biopsy. Objective: (i) To monitor the implementation of local guidelines; (ii) To compare UC with EM and (iii) To identify areas for improvement. Methods: Decoy cell and EM positive cases were retrieved from the WinPath database for new renal transplant recipients (n = 55) during 1^st November 2004 to 31^st October 2005 in Royal Free Hospital. Plasma PCR was retrieved for positive cases. Results: Up to eight samples were sent for UC at random intervals from 47 patients, and up to 7 were sent for EM from 42 patients. Eleven were UC‐positive and one was EM‐positive. PCR was not requested in UC‐positive cases and 3 out of 10 were positive retrospectively. The EM‐positive case was PCR‐positive but UC‐negative. Discussion: Urine Cytology is more appropriate and cost effective for screening than Electron Microscopy. During the period covered by this audit, samples were sent in an inconsistent fashion after allograft dysfunction rather than for screening. A screening protocol has been agreed and a re‐audit is planned.